IDEAYA Biosciences, Inc. — Q2 2019 Form 10-Q
Reporting period: Three and six months ended June 30, 2019. IDEAYA is a clinical-stage oncology precision-medicine company with no approved products and no revenue to date. The quarter included its May 2019 IPO and conversion of all preferred shares into common stock.
Financial performance
| Metric | Q2 2019 | Q2 2018 | Six months 2019 | Six months 2018 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Research and development expense | $8.9 million | $6.4 million | $16.9 million | $11.6 million |
| General and administrative expense | $2.4 million | $1.1 million | $4.5 million | $2.0 million |
| Operating loss | $11.2 million | $7.6 million | $21.3 million | $13.7 million |
| Net loss | $10.7 million | $7.0 million | $20.2 million | $12.7 million |
| Interest income | $0.6 million | $0.6 million | $1.1 million | $0.9 million |
| Basic and diluted net loss per share | $1.30 | $7.47 | $4.32 | $14.41 |
Operating margins are not meaningful because the company had no revenue. Q2 R&D expense increased 38%, primarily from clinical-trial and contract research/manufacturing costs, personnel, and consulting. G&A expense rose 109%, reflecting public-company costs, added staff, and higher insurance and professional fees. The smaller loss per share versus 2018 largely reflects the increased weighted-average share count following the IPO and share conversion; it should not be read as improved operating performance.
Financial position, cash flow, and liquidity
- At June 30, 2019, cash and cash equivalents were $88.1 million and short-term marketable securities were $32.0 million, totaling approximately $120.2 million in cash, cash equivalents, and securities.
- Six-month operating cash use was $20.1 million, compared with $11.5 million in the prior-year period. The increase chiefly reflects higher operating spending; prepaid expenses also increased.
- Cash, cash equivalents, and restricted cash increased $67.6 million during the first half, primarily reflecting $50.8 million of IPO proceeds and net cash from marketable-security activity.
- Current assets were $122.6 million and current liabilities were $6.5 million. The company reported no borrowings; operating lease liabilities totaled $7.4 million, including $1.2 million current and $6.2 million long-term.
- Accumulated deficit was $70.7 million. Management stated that available cash, cash equivalents, and short-term securities were expected to fund planned operations for at least 12 months from issuance of the financial statements.
Material changes and notable items
- The IPO closed May 28, 2019: 5.75 million shares were sold at $10 per share for $57.5 million gross proceeds. Preferred stock converted into 13.1 million common shares. The company reported approximately $50.2 million net proceeds after underwriting discounts and offering costs.
- IDEAYA adopted the new lease standard in January 2019, recognizing right-of-use assets and lease liabilities. No material effect on operating results or cash flows was reported.
- Management reported effective disclosure controls as of June 30, 2019 and no material change in internal control over financial reporting during the quarter.
- No material litigation was reported; management said ordinary-course claims were not expected to have a material adverse effect.
Outlook, development plans, and key risks
- Management expects operating losses and R&D spending to continue and increase as programs advance. No revenue or profitability guidance was provided.
- IDE196, a PKC inhibitor licensed from Novartis, is being evaluated in a company-led Phase 1/2 trial for GNAQ/GNA11-mutated solid tumors. The company anticipated selecting a Phase 2 dose by year-end 2019. It also reported plans, subject to preclinical results, for additional indications and combination studies.
- The company expected to select a MAT2A inhibitor development candidate for IND-enabling studies in the second half of 2019 and file an IND in the first half of 2020; it expected to designate a Pol-theta inhibitor candidate for IND-enabling studies in the first half of 2020.
- Management cited significant development, regulatory, manufacturing, enrollment, intellectual-property, and financing uncertainties. The company depends on CROs and CMOs and has no in-house clinical or commercial manufacturing capability.
- IDE196 development partly depends on Novartis trial data that IDEAYA does not control. In the filing’s later-dated update, five of 28 evaluable patients in Novartis’s monotherapy BID cohort remained on therapy for more than two years; the company cautioned that trial data and outcomes remain uncertain.
- Additional capital may be needed; future financing could dilute shareholders, impose debt restrictions, or require the company to delay, reduce, or discontinue programs. Management’s 12-month runway estimate is based on its current plan and is not assurance of future financing availability.
- Other material risks include clinical-trial failure or delay, adverse effects, reliance on companion diagnostics and third parties, competition, and the possibility that targeted or synthetic-lethality approaches do not translate into clinical benefit.
Investor verification priorities
- Track IDE196 trial enrollment, dose selection, safety, response durability, and whether Novartis continues to provide usable clinical data.
- Compare operating cash use and R&D spending with the stated cash runway as clinical programs expand; verify any subsequent financing plans or transactions.
- Confirm MAT2A and Pol-theta candidate-selection and IND timelines against later company disclosures.
- Reconcile IPO proceeds presentation: the filing cites approximately $50.2 million net after offering costs, while the cash-flow statement reports $50.8 million of IPO proceeds net of issuance costs.
- Monitor lease commitments, potential dilution from equity awards and future fundraising, and the timing of shares becoming eligible for sale after IPO lock-ups.